Ashfield Capital Partners’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $359K | Hold |
4,727
| – | – | 0.03% | 192 |
|
|
2022
Q2 | $400K | Sell |
4,727
-147
| -3% | -$12.9K | 0.03% | 188 |
|
|
2022
Q1 | $428K | Hold |
4,874
| – | – | 0.03% | 195 |
|
|
2021
Q4 | $426K | Buy |
4,874
+25
| +0.5% | +$2.08K | 0.03% | 198 |
|
|
2021
Q3 | $397K | Sell |
4,849
-359
| -7% | -$32.3K | 0.03% | 201 |
|
|
2021
Q2 | $475K | Sell |
5,208
-1,491
| -22% | -$133K | 0.03% | 195 |
|
|
2021
Q1 | $573K | Hold |
6,699
| – | – | 0.05% | 179 |
|
|
2020
Q4 | $633K | Sell |
6,699
-45
| -0.7% | -$3.93K | 0.05% | 167 |
|
|
2020
Q3 | $586K | Sell |
6,744
-293
| -4% | -$25.4K | 0.05% | 164 |
|
|
2020
Q2 | $615K | Sell |
7,037
-3,346
| -32% | -$289K | 0.06% | 158 |
|
|
2020
Q1 | $856K | Sell |
10,383
-540
| -5% | -$48.2K | 0.1% | 129 |
|
|
2019
Q4 | $1.03M | Sell |
10,923
-560
| -5% | -$50.2K | 0.1% | 131 |
|
|
2019
Q3 | $998K | Buy |
+11,483
| New | +$1.03M | 0.11% | 135 |
|
|
2019
Q2 | – | Sell |
-14,803
| Closed | -$1.25M | – | 136 |
|
|
2019
Q1 | $1.27M | Sell |
14,803
-1,198
| -7% | -$96.2K | 0.14% | 125 |
|
|
2018
Q4 | $1.23M | Sell |
16,001
-1,449
| -8% | -$113K | 0.16% | 126 |
|
|
2018
Q3 | $1.35M | Sell |
17,450
-8,814
| -34% | -$652K | 0.15% | 125 |
|
|
2018
Q2 | $1.78M | Sell |
26,264
-97
| -0.4% | -$6.69K | 0.22% | 105 |
|
|
2018
Q1 | $1.91M | Buy |
26,361
+6,994
| +36% | +$532K | 0.25% | 94 |
|
|
2017
Q4 | $1.46M | Buy |
19,367
+2,553
| +15% | +$193K | 0.19% | 122 |
|
|
2017
Q3 | $1.29M | Sell |
16,814
-6
| -0% | -$453 | 0.17% | 123 |
|
|
2017
Q2 | $1.26M | Sell |
16,820
-3,871
| -19% | -$274K | 0.17% | 128 |
|
|
2017
Q1 | $1.38M | Sell |
20,691
-1,767
| -8% | -$118K | 0.19% | 123 |
|
|
2016
Q4 | $1.47M | Sell |
22,458
-13,627
| -38% | -$884K | 0.14% | 123 |
|
|
2016
Q3 | $2.55M | Sell |
36,085
-3,263
| -8% | -$238K | 0.21% | 95 |
|
|
2016
Q2 | $2.91M | Sell |
39,348
-108,784
| -73% | -$7.52M | 0.23% | 85 |
|
|
2016
Q1 | $9.62M | Sell |
148,132
-112,535
| -43% | -$7.66M | 0.7% | 49 |
|
|
2015
Q4 | $20.1M | Sell |
260,667
-90,084
| -26% | -$7.16M | 1.37% | 20 |
|
|
2015
Q3 | $28.9M | Sell |
350,751
-30,848
| -8% | -$2.75M | 1.86% | 12 |
|
|
2015
Q2 | $33.6M | Buy |
381,599
+68,972
| +22% | +$6.33M | 1.84% | 12 |
|
|
2015
Q1 | $27.6M | Sell |
312,627
-50,018
| -14% | -$4.44M | 1.47% | 21 |
|
|
2014
Q4 | $30.1M | Buy |
362,645
+333,186
| +1,131% | +$27.6M | 1.45% | 25 |
|
|
2014
Q3 | $2.48M | Buy |
29,459
+363
| +1% | +$29.4K | 0.12% | 104 |
|
|
2014
Q2 | $2.36M | Sell |
29,096
-1,770
| -6% | -$139K | 0.11% | 108 |
|
|
2014
Q1 | $2.35M | Sell |
30,866
-315
| -1% | -$23K | 0.11% | 105 |
|
|
2013
Q4 | $2.25M | Buy |
31,181
+311
| +1% | +$21.6K | 0.11% | 105 |
|
|
2013
Q3 | $2.12M | Sell |
30,870
-115
| -0.4% | -$7.61K | 0.11% | 105 |
|
|
2013
Q2 | $1.96M | Buy |
+30,985
| New | +$2.02M | 0.11% | 108 |
|
Other funds holding NVS
Ashfield Capital Partners's NVS Position: Q3 2022 in Review
Ashfield Capital Partners held its Novartis (NVS) position steady in Q3 2022 at 4,727 shares worth $359K. The position accounts for 0.03% of the portfolio, ranked #192.
Ashfield Capital Partners first reported a position in NVS in Q2 2013 and has held it in 37 quarters since. The position peaked at $33.6M in Q2 2015. 1,088 funds tracked by Wall St. Rank hold NVS as of Q3 2022.
- Ashfield Capital Partners held 4,727 shares of Novartis worth $359K as of Q3 2022.
- Ashfield Capital Partners left its Novartis share count unchanged in Q3 2022.
- Novartis made up 0.03% of Ashfield Capital Partners's portfolio in Q3 2022, its #192 holding.
- Ashfield Capital Partners first reported a position in Novartis in Q2 2013 and has held it in 37 quarters since.
- Ashfield Capital Partners's Novartis position peaked at $33.6M in Q2 2015.
- 1,088 funds tracked by Wall St. Rank held Novartis as of Q3 2022.
Based on Ashfield Capital Partners's 13F filing for Q3 2022, filed 10 Nov 2022.